By specifically targeting the ErbB2 N-glycosylation sites in the trastuzumab-binding domain, ST6Gal1-mediated aberrant α-2,6-sialylation actively tunes the resistance of ErbB2-driven gastric cancer cells to trastuzumab. Here, ERBB2 is linked to gastric cancer.